Stockscreener 앱 받기
44.10
0.23%
0.10
Dianthus Therapeutics Inc 주식(DNTH)의 최신 뉴스
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Up 47.4% in December - MarketBeat
First Week of March 20th Options Trading For Dianthus Therapeutics (DNTH) - Nasdaq
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 6.1%Should You Sell? - MarketBeat
Published on: 2026-01-15 20:27:08 - baoquankhu1.vn
Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.
Is Dianthus Therapeutics Inc. currently under institutional pressureJuly 2025 Setups & Growth Oriented Trading Recommendations - bollywoodhelpline.com
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year HighShould You Buy? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at $45.56 By Investing.com - Investing.com Nigeria
Trading Recap: How Dianthus Therapeutics Inc stock reacts to bond yieldsWeekly Stock Summary & Free Safe Capital Growth Stock Tips - Bộ Nội Vụ
Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 12%Here's What Happened - MarketBeat
Breakout Zone: Whats the RSI of Dianthus Therapeutics Inc stock2025 Risk Factors & High Accuracy Swing Trade Signals - baoquankhu1.vn
Dianthus Therapeutics stock hits 52-week high at $45.56 - Investing.com
Fed Watch: How Dianthus Therapeutics Inc stock responds to policy changesJuly 2025 Snapshot & Weekly High Momentum Picks - Bộ Nội Vụ
Assessing Dianthus Therapeutics (DNTH) Valuation As Price To Book Sits Near 3x And Shares Show Mixed Returns - Yahoo Finance
Dianthus Therapeutics (DNTH) Investor Outlook: A Biotechnology Gem with a 66.92% Upside - DirectorsTalk Interviews
Will Dianthus Therapeutics Inc. stock gain from lower inflation2025 Institutional Moves & Low Risk Profit Maximizing Plans - Улправда
Can Dianthus Therapeutics Inc. stock hit record highs againJuly 2025 Sentiment & Risk Managed Investment Entry Signals - Улправда
Why Dianthus Therapeutics Inc. stock could outperform in 2025Portfolio Update Summary & Real-Time Volume Triggers - Улправда
DNTH: Analyst Raises Price Target to $63, Maintains Buy Rating | - GuruFocus
Truist Financial Raises Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $63.00 - MarketBeat
Market Outlook: What technical charts say about Dianthus Therapeutics Inc. stock2025 Analyst Calls & Long-Term Investment Growth Plans - Улправда
Cash per share of Dianthus Therapeutics, Inc. – LS:A3ERZ4 - TradingView — Track All Markets
San Gabriel Valley Tribune - FinancialContent
Laser Focus WorldDianthus Therapeutics, Inc.Common Stock (Nasdaq:DNTH) Stock Quote - FinancialContent
Why Dianthus Therapeutics Inc. (87E) stock fits value portfolios2026 world cup usa national team quarterfinals goalkeepers high defensive line odds analysis breakdown - Улправда
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Dianthus Therapeutics Enters Oversold Territory (DNTH) - Nasdaq
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Biotech targeting severe autoimmune diseases to present at JPM event - Stock Titan
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 3.3% – Here’s Why - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 3.3%What's Next? - MarketBeat
Dianthus Therapeutics, Inc. $DNTH Stake Lessened by Moody Aldrich Partners LLC - MarketBeat
ETF Watch: Why Dianthus Therapeutics Inc stock could outperform in 2025Market Movement Recap & AI Enhanced Execution Alerts - moha.gov.vn
Dianthus, Nanjing Leads Biolabs initiate Phase 1 trial of LBL-047 - MSN
Leads Biolabs and Dianthus Therapeutics Initiate Phase 1 Trial for LBL-047 (DNTH212), a Bifunctional Fusion Protein Targeting Autoimmune Disorders - Quiver Quantitative
Leads Biolabs And Dianthus Therapeutics Announce Initiation Of Phase 1 Trial Of LBL-047 (Dnth212) In Healthy Volunteers And Patients With Systemic Lupus Erythematosus - TradingView — Track All Markets
New lupus drug test begins, aiming for simple self-injections every month - Stock Titan
Wedbush Reiterates Outperform Rating for Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics Earnings Notes - Trefis
How big funds are accumulating Dianthus Therapeutics Inc. (87E) stockPortfolio Return Report & High Conviction Investment Ideas - Улправда
Aug Closing: How big funds are accumulating Dianthus Therapeutics Inc. (87E) stockJuly 2025 Recap & Daily Profit Focused Screening - Улправда
Wall Street Recap: Is Dianthus Therapeutics Inc. stock overvalued by current metricsCPI Data & AI Enhanced Trading Signals - Улправда
First Week of August 2026 Options Trading For Dianthus Therapeutics (DNTH) - Nasdaq
Bain Capital Life Sciences Investors LLC Has $46.24 Million Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics, Inc. $DNTH Shares Sold by 5AM Venture Management LLC - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
What drives Dianthus Therapeutics Inc 87E stock priceLow Risk Investment Ideas & Low Cost Trading Tips - earlytimes.in
EBIT per share of Dianthus Therapeutics, Inc. – GETTEX:87E - TradingView — Track All Markets
Dianthus Therapeutics (NASDAQ:DNTH) CFO Ryan Savitz Sells 20,000 Shares - MarketBeat
Dianthus Therapeutics CFO & CBO Ryan Savitz Sells 20,000 Shares - TradingView — Track All Markets
CFO Savitz Sells 20,000 ($903.6K) Of Dianthus Therapeutics Inc [DNTH] - TradingView
Ashland, Bitdeer, and More Stocks See Action From Activist Investors - Barron's
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week HighHere's Why - MarketBeat
Nothing is Better Than Dianthus Therapeutics Inc (DNTH) stock at the moment - setenews.com
27,003 Shares in Dianthus Therapeutics, Inc. $DNTH Bought by XTX Topco Ltd - MarketBeat
Geode Capital Management LLC Has $9.04 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 45.0 USD By Investing.com - Investing.com Nigeria
4.73%
0.92%
자본화:
|
볼륨(24시간):